← All trials
NCT05575999
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 12, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kansas City Heart Rhythm Research FoundationLead sponsor
- Kansas City Heart Rhythm Research FoundationOverall official - principal investigator
- Loma Linda UniversityCollaborator
- Kansas City Heart Rhythm Research FoundationOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.